Hydroxytamoxifen is an active metabolite produced from tamoxifen, which has been shown to increase FASL (Fas ligand, a pro-apoptotic factor) expression, leading to reduce in vitro cellular growth and decreased tumor progression in xenograft models. The gene discussed is FASLG; the disease is neoplasm.